Hoffmann-La Roche Limited

Gold Sponsor

Focus: Psychiatric disorders, Neurodegenerative disorders, Neurodevelopmental disorders

http://www.rochecanada.com

Psychiatric disorders, including schizophrenia and treatment-resistant depression. In schizophrenia we target negative symptoms and cognition improvement (while most of existing treatment target positive symptoms). Treatment-resistant depression include the ~35% of depressive patients that not respond to standard of care.

Neurodegenerative disorders, including Parkinson’s disease, Alzheimer’s disease and Multiple Sclerosis. Roche focuses on an early intervention and selection of patients eligible for a specific treatment based on biomarkers.  

Neurodevelopmental disorders, including autism spectrum disorders, Down syndrome and Fragile X. In these diseases of the development of the brain we are focusing on the treatment of core symptoms, like social interaction, communication deficits and restricted repetitive behaviours.

From our approach to clinical trials for new drug therapies, to industry partnerships and community involvement, Roche Canada is a leader in providing pharmaceutical and diagnostic solutions that make a profound difference in people’s lives.  Our innovative approach improves the effectiveness and efficiency of the healthcare system in the diagnosis, treatment and management of acute and long-term disease.

Roche Canada employs approximately 1,000 people across the country, with its pharmaceuticals head office located in Mississauga, Ontario and diagnostics division based in Laval, Quebec.  For more information, please visit www.rochecanada.com.